Powder: -20°C for 3 years
In solvent: -80°C for 2 years
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
Description | ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy. |
Targets&IC50 | Eph family tyrosine kinase:11 nM |
In vitro | ALW-II-41-27 inhibits Ba/F3 cells (EC50<500 nM) transformed with Tel fusions of Kit, EphA3, Fms, KDR, FLT1, FGR, Src, Bmx, Lyn, and Bcr-Abl. ALW-II-41-27 has cross-reactivity with Bcr-Abl. ALW-II-41-27 inhibits b-Raf, CSF1R, DDR1, DDR2, EphA2, EphA8, EphB1, EphB2, Kit, EphB3, Frk, Lck, EphA5, p38α, p38β, PDGFRβ, PDGFRα, and Raf1. |
Synonyms | Eph receptor tyrosine kinase inhibitor |
Molecular Weight | 607.7 |
Formula | C32H32F3N5O2S |
CAS No. | 1186206-79-0 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 47 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ALW-II-41-27 1186206-79-0 Tyrosine Kinase/Adaptors Ephrin Receptor ALWII4127 Inhibitor Eph receptor tyrosine kinase inhibitor inhibit ALW II 41 27 inhibitor